Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet

Free Radical Biology and Medicine

Volumn 49, Issue 7, 2010, Pages 1212-1220

  Prasanthi, Jaya R P ^a   Dasari, Bhanu ^a   Marwarha, Gurdeep ^a   Larson, Tyler ^a   Chen, Xuesong ^a   Geiger, Jonathan D ^a   Ghribi, Othman ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Amyloid; Adenosine receptors; Alzheimer's disease; Caffeine; Cholesterol; Endoplasmic reticulum stress; Free radicals; Oxidative stress; Tau

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; AMYLOID BETA PROTEIN; ANTIOXIDANT; CAFFEINE; CHOLESTEROL; FREE RADICAL; GLUTATHIONE; ISOPROSTANE; REACTIVE OXYGEN METABOLITE; RYANODINE RECEPTOR; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT INTAKE; HIPPOCAMPUS; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RABBIT; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; CAFFEINE; CHOLESTEROL, DIETARY; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM; HIPPOCAMPUS; HUMANS; MALE; OXIDATIVE STRESS; RABBITS; REACTIVE OXYGEN SPECIES; RECEPTOR, ADENOSINE A1; TAU PROTEINS;

MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

EID: 77956180469     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.07.007     Document Type: Article

References (69)

1. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
2. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
3. Levi O., Lutjohann D., Devir A., von B.K., Hartmann T., Michaelson D.M. Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation. J. Neurochem. 2005, 95:987-997.
4. Eto M., Watanabe K., Chonan N., Ishii K. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 1988, 72:123-128.
5. Murakami K., Shimizu M., Yamada N., Ishibashi S., Shimano H., Yazaki Y., Akanuma Y. Apolipoprotein E polymorphism is associated with plasma cholesterol response in a 7-day hospitalization study for metabolic and dietary control in NIDDM. Diab. Care 1993, 16:564-569.
6. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cognit. Disord. 2009, 28:75-80.
7. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den B.H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van B.C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
8. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De D.P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van B.C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
9. Castellani R.J., Zhu X., Lee H.G., Moreira P.I., Perry G., Smith M.A. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Rev. Neurother. 2007, 7:473-485.
10. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl Acad. Sci. USA 1994, 91:5710-5714.
11. Smith M.A., Richey P.L., Taneda S., Kutty R.K., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann. NY Acad. Sci. 1994, 738:447-454.
12. Sultana R., Butterfield D.A. Role of oxidative stress in the progression of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:341-353.
13. Smith M.A., Zhu X., Tabaton M., Liu G., McKeel D.W., Cohen M.L., Wang X., Siedlak S.L., Dwyer B.E., Hayashi T., Nakamura M., Nunomura A., Perry G. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 2010, 19:363-372.
14. Aytan N., Jung T., Tamturk F., Grune T., Kartal-Ozer N. Oxidative stress related changes in the brain of hypercholesterolemic rabbits. Biofactors 2008, 33:225-236.
15. Greco A., Minghetti L., Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem. Res. 2000, 25:1357-1364.
16. Woltjer R.L., Nghiem W., Maezawa I., Milatovic D., Vaisar T., Montine K.S., Montine T.J. Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. J. Neurochem. 2005, 93:1047-1056.
17. He S., Yaung J., Kim Y.H., Barron E., Ryan S.J., Hinton D.R. Endoplasmic reticulum stress induced by oxidative stress in retinal pigment epithelial cells. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:677-683.
18. Lindholm D., Wootz H., Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ. 2006, 13:385-392.
19. Oyadomari S., Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004, 11:381-389.
20. Sparks D.L., Scheff S.W., Hunsaker J.C., Liu H., Landers T., Gross D.R. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 1994, 126:88-94.
21. Ghribi O., Golovko M.Y., Larsen B., Schrag M., Murphy E.J. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J. Neurochem. 2006, 99:438-449.
22. Ghribi O., Larsen B., Schrag M., Herman M.M. High cholesterol content in neurons increases BACE, β-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp. Neurol. 2006, 200:460-467.
23. Jaya Prasanthi R.P., Schommer E., Thomasson S., Thompson A., Feist G., Ghribi O. Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech. Ageing Dev. 2008, 129:649-655.
24. Sharma S., Prasanthi R.P.J., Schommer E., Feist G., Ghribi O. Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol. Dis. 2008, 32:426-432.
25. Fredholm B.B., Chen J.F., Masino S.A., Vaugeois J.M. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol. 2005, 45:385-412.
26. Camouse M.M., Hanneman K.K., Conrad E.P., Baron E.D. Protective effects of tea polyphenols and caffeine. Expert Rev. Anticancer Ther. 2005, 5:1061-1068.
27. Arendash G.W., Schleif W., Rezai-Zadeh K., Jackson E.K., Zacharia L.C., Cracchiolo J.R., Shippy D., Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006, 142:941-952.
28. Arendash G.W., Mori T., Cao C., Mamcarz M., Runfeldt M., Dickson A., Rezai-Zadeh K., Tane J., Citron B.A., Lin X., Echeverria V., Potter H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J. Alzheimers Dis. 2009, 17:661-680.
29. Cao C., Cirrito J.R., Lin X., Wang L., Verges D.K., Dickson A., Mamcarz M., Zhang C., Mori T., Arendash G.W., Holtzman D.M., Potter H. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J. Alzheimers Dis. 2009, 17:681-697.
30. Kleiber M. Body size and metabolism. Hilgardia 1932, 6:315-351.
31. Barone J.J., Roberts H.R. Caffeine consumption. Food Chem. Toxicol. 1996, 34:119-129.
32. Rush J.W., Quadrilatero J., Levy A.S., Ford R.J. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp. Biol. Med. (Maywood. ) 2007, 232:814-822.
33. Malhotra J.D., Miao H., Zhang K., Wolfson A., Pennathur S., Pipe S.W., Kaufman R.J. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc. Natl Acad. Sci. USA 2008, 105:18525-18530.
34. McCullough K.D., Martindale J.L., Klotz L.O., Aw T.Y., Holbrook N.J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol. 2001, 21:1249-1259.
35. Ghribi O. The role of the endoplasmic reticulum in the accumulation of beta-amyloid peptide in Alzheimer's disease. Curr. Mol. Med. 2006, 6:119-133.
36. Pappolla M.A., Smith M.A., Bryant-Thomas T., Bazan N., Petanceska S., Perry G., Thal L.J., Sano M., Refolo L.M. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radic. Biol. Med. 2002, 33:173-181.
37. Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol. Sci. 2008, 29:609-615.
38. Zafrilla P., Mulero J., Xandri J.M., Santo E., Caravaca G., Morillas J.M. Oxidative stress in Alzheimer patients in different stages of the disease. Curr. Med. Chem. 2006, 13:1075-1083.
39. Sekler A., Jimenez J.M., Rojo L., Pastene E., Fuentes P., Slachevsky A., Maccioni R.B. Cognitive impairment and Alzheimer's disease: links with oxidative stress and cholesterol metabolism. Neuropsychiatr. Dis. Treat. 2008, 4:715-722.
40. Bermejo P., Martin-Aragon S., Benedi J., Susin C., Felici E., Gil P., Ribera J.M., Villar A.M. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from mild cognitive impairment. Free Radic. Res. 2008, 42:162-170.
41. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA 2004, 101:2070-2075.
42. Feng B., Yao P.M., Li Y., Devlin C.M., Zhang D., Harding H.P., Sweeney M., Rong J.X., Kuriakose G., Fisher E.A., Marks A.R., Ron D., Tabas I. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat. Cell Biol. 2003, 5:781-792.
43. Johnson R.J., Xiao G., Shanmugaratnam J., Fine R.E. Calreticulin functions as a molecular chaperone for the beta-amyloid precursor protein. Neurobiol. Aging 2001, 22:387-395.
44. Hamos J.E., Oblas B., Pulaski-Salo D., Welch W.J., Bole D.G., Drachman D.A. Expression of heat shock proteins in Alzheimer's disease. Neurology 1991, 41:345-350.
45. Yoo B.C., Fountoulakis M., Dierssen M., Lubec G. Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down syndrome: dysregulation of T-complex protein 1. J. Neural Transm. Suppl. 2001, 321-334.
46. Tamagno E., Bardini P., Obbili A., Vitali A., Borghi R., Zaccheo D., Pronzato M.A., Danni O., Smith M.A., Perry G., Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 2002, 10:279-288.
47. Tamagno E., Guglielmotto M., Bardini P., Santoro G., Davit A., Di S.D., Danni O., Tabaton M. Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiol. Dis. 2003, 14:291-301.
48. Devasagayam T.P., Kamat J.P., Mohan H., Kesavan P.C. Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim. Biophys. Acta 1996, 1282:63-70.
49. Lee C. Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation. Clin. Chim. Acta 2000, 295:141-154.
50. Shi X., Dalal N.S., Jain A.C. Antioxidant behaviour of caffeine: efficient scavenging of hydroxyl radicals. Food Chem. Toxicol. 1991, 29:1-6.
51. 2+ release from the intracellular stores of hepatocytes is not mediated by ryanodine receptors. Biochem. J. 1993, 291:799-801.
52. Querfurth H.W., Jiang J., Geiger J.D., Selkoe D.J. Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. J. Neurochem. 1997, 69:1580-1591.
53. Querfurth H.W., Haughey N.J., Greenway S.C., Yacono P.W., Golan D.E., Geiger J.D. Expression of ryanodine receptors in human embryonic kidney (HEK293) cells. Biochem. J. 1998, 334:79-86.
54. Butcher R.W., Sutherland E.W. Adenosine 3β, 5β-phosphate in biological materials. I. Purification and properties of cyclic 3β, 5β-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3β, 5β-phosphate in human urine. J. Biol. Chem. 1962, 237:1244-1250.
55. Rudolphi K.A., Keil M., Fastbom J., Fredholm B.B. Ischaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci. Lett. 1989, 103:275-280.
56. Angulo E., Casado V., Mallol J., Canela E.I., Vinals F., Ferrer I., Lluis C., Franco R. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 2003, 13:440-451.
57. Svenningsson P., Nomikos G.G., Fredholm B.B. The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. J. Neurosci. 1999, 19:4011-4022.
58. Deckert J., Abel F., Kunig G., Hartmann J., Senitz D., Maier H., Ransmayr G., Riederer P. Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity. Neurosci. Lett. 1998, 244:1-4.
59. Kalaria R.N., Sromek S., Wilcox B.J., Unnerstall J.R. Hippocampal adenosine A1 receptors are decreased in Alzheimer's disease. Neurosci. Lett. 1990, 118:257-260.
60. Ulas J., Brunner L.C., Nguyen L., Cotman C.W. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience 1993, 52:843-854.
61. Ikeda M., Mackay K.B., Dewar D., McCulloch J. Differential alterations in adenosine A1 and kappa 1 opioid receptors in the striatum in Alzheimer's disease. Brain Res. 1993, 616:211-217.
62. Cunha R.A., Johansson B., van d.P.I., Sebastiao A.M., Ribeiro J.A., Fredholm B.B. Evidence for functionally important adenosine A2a receptors in the rat hippocampus. Brain Res. 1994, 649:208-216.
63. 3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1996, 353:261-271.
64. Rosin D.L., Hettinger B.D., Lee A., Linden J. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 2003, 61:S12-S18.
65. Canas P.M., Porciuncula L.O., Cunha G.M., Silva C.G., Machado N.J., Oliveira J.M., Oliveira C.R., Cunha R.A. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J. Neurosci. 2009, 29:14741-14751.
66. Xu K., Bastia E., Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2005, 105:267-310.
67. Chen X., Gawryluk J.W., Wagener J.F., Ghribi O., Geiger J.D. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J. Neuroinflammation 2008, 5:12.
68. Chen X., Lan X., Roche I., Liu R., Geiger J.D. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J. Neurochem. 2008, 107:1147-1157.
69. Chen X., Ghribi O., Geiger J.D., Liu R., Geiger J.D. Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J. Alzheimers Dis. 2010, 20(suppl 1):S127-S141.